Tag Archives: Labiotech.eu

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »

Kite snags deal with Dutch biotech Gadeta to advance brand new CAR T-cell treatment for solid tumors.

The News: Kite Pharma Inc. (El Segundo CA) reportedly will support Gadeta BV (Utrecht NLD) in the development of a new type of CAR T-cell therapy that could be more… Read more »

Tiny Swedish biotech not taking back seat to US in Alzheimer’s race. How to buy it.

The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »

The growing link between blockchain and the safety of our genomic data; a primer.

The News: As the cost of sequencing an individual genome gets lower and more people have access to their genomic data, a question has arisen about data ownership. Namely, who… Read more »

Update: Where does Brexit leave European pharma, now that the EU has excluded the UK from drug approvals?

A European decision to exclude Britain from the EU’s drug approval system from beginning 30, 2019–the day after Brexit–has raised alarm among drugmakers, who fear the abrupt change could disrupt… Read more »

First FDA-approved gene-therapy procedure for inherited blindness performed in US. Advance is fantastic news, but same quandary: Who can afford it?

The News: Massachusetts Eye and Ear, a Harvard teaching hospital based in Boston, recently became the first institution to treat a patient’s inherited retinal disorder with gene therapy. The patient,… Read more »

Join a clinical trial? The success rate of such trials is higher than you thought, but still awfully low overall; especially for Alzheimer’s.

The News: Instead of less than 10% of drugs reaching the market, a new study has found that almost 15% of new compounds pass clinical trial–which still suggests that it’s… Read more »

Investor Alert: Qiagen grabs Spanish biotech STAT-Dx in quest for new and better diagnostic tests. My personal take.

The News: Molecular diagnostics company Qiagen NV (Hilden DEU) has agreed to acquire biotech STAT-Dx SL (Barcelona) for up to €153 million–over 3 times the total funding the Spanish company has raised… Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »